ArticleJAMA network open2020
Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically Indeterminate Adnexal Masses.
Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02962596 (European Multicenter Validation of an ADNEXMR SCORING System for Characterizing Adnexal Masses), which is not on this map. Cited by 126 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
European Multicenter Validation of an ADNEXMR SCORING System for Characterizing Adnexal Masses: EURAD-MR Classification
Who cites it
126 citing papers in PubMed, 4 syntheses or guidelines pooled it, 267 citations in OpenAlex.
- European Society of Urogenital Radiology (ESUR) guidelines on MR imaging prior to fertility-sparing treatments in patients with cervical, endometrial, and ovarian cancers.European radiology · 2025Guideline
- Node-RADS: a systematic review and meta-analysis of diagnostic performance, category-wise malignancy rates, and inter-observer reliability.European radiology · 2025Pooled it
- Diagnostic performance of the O-RADS MRI system for magnetic resonance imaging in discriminating benign and malignant adnexal lesions: a systematic review, meta-analysis, and meta-regression.Diagnostic and interventional radiology (Ankara, Turkey) · 2025Pooled it
- Indirect comparison of the diagnostic performance ofBMC cancer · 2021Pooled it
- Improving diagnostic performance of O-RADS MRI: semi-quantitative intensity curves vs visual assessment of enhancement.European radiology · 2026Article
- Diagnostic accuracy of a modified non-contrast O-RADS MRI scoring system: a retrospective study.Insights into imaging · 2026Article
- Gynecologic imaging errors and pitfalls: how to avoid misdiagnosis on pelvic MRI.Insights into imaging · 2026Review
- The role of apparent diffusion coefficient histogram analysis in improving O-RADS magnetic resonance imaging classification of adnexal lesions: a retrospective diagnostic accuracy study.Translational cancer research · 2026Article
- Magnetic resonance biomarkers in detection and characterisation of ovarian cancer: is magnetic resonance spectroscopy ready for clinical use?Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- O-RADS for assessment of adnexal lesions: current status, challenges and future directions.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Diagnostic reliability of O-RADS score based on non-dynamic contrast-enhanced MRI and apparent diffusion coefficient in characterization of adnexal masses.BMC medical imaging · 2026Article
- Exploring the value of the ovarian-adnexal reporting and data system combined with tumor markers in the differential diagnosis of benign and malignant ovarian-adnexal tumors.Molecular and clinical oncology · 2026Article
- Investigation of multimodal deep learning models for predicting ovarian tumor malignancy based on ultrasound images and clinical information - a comprehensive comparative study against readers and O-RADS.BMC medical imaging · 2026Article
- Refining O-RADS MRI: beyond malignancy risk.European radiology · 2026Article
- Transforming a clinical study database into a structured database adapted to artificial intelligence applications.Insights into imaging · 2026Article
- ESUR female pelvis group approach to cystic female pelvic lesions.Insights into imaging · 2026Article
- Article
- RADS ALPHABET: news and tips for young and general radiologists.Insights into imaging · 2026Article
- Role of Imaging Techniques in Ovarian Cancer Diagnosis: Current Approaches and Future Directions.Cancers · 2026Review
- A Simple O-RADS-Based Ultrasound Scoring System for Risk Stratification of Ovarian Cystic Lesions: A Multicenter Study.International journal of women's health · 2026Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 15 institutions in 7 countries.
Funding
Abstract
Importance: Approximately one-quarter of adnexal masses detected at ultrasonography are indeterminate for benignity or malignancy, posing a substantial clinical dilemma. Objective: To validate the accuracy of a 5-point Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) score for risk stratification of adnexal masses. Design, Setting, and Participants: This multicenter cohort study was conducted between March 1, 2013, and March 31, 2016. Among patients undergoing expectant management, 2-year follow-up data were completed by March 31, 2018. A routine pelvic MRI was performed among consecutive patients referred to characterize a sonographically indeterminate adnexal mass according to routine diagnostic practice at 15 referral centers. The MRI score was prospectively applied by 2 onsite readers and by 1 reader masked to clinical and ultrasonographic data. Data analysis was conducted between April and November 2018. Main Outcomes and Measures: The primary end point was the joint analysis of true-negative and false-negative rates according to the MRI score compared with the reference standard (ie, histology or 2-year follow-up). Results: A total of 1340 women (mean [range] age, 49 [18-96] years) were enrolled. Of 1194 evaluable women, 1130 (94.6%) had a pelvic mass on MRI with a reference standard (surgery, 768 [67.9%]; 2-year follow-up, 362 [32.1%]). A total of 203 patients (18.0%) had at least 1 malignant adnexal or nonadnexal pelvic mass. No invasive cancer was assigned a score of 2. Positive likelihood ratios were 0.01 for score 2, 0.27 for score 3, 4.42 for score 4, and 38.81 for score 5. Area under the receiver operating characteristic curve was 0.961 (95% CI, 0.948-0.971) among experienced readers, with a sensitivity of 0.93 (95% CI, 0.89-0.96; 189 of 203 patients) and a specificity of 0.91 (95% CI, 0.89-0.93; 848 of 927 patients). There was good interrater agreement among both experienced and junior readers (κ = 0.784; 95% CI, 0.743-0824). Of 580 of 1130 women (51.3%) with a mass on MRI and no specific gynecological symptoms, 362 (62.4%) underwent surgery. Of them, 244 (67.4%) had benign lesions and a score of 3 or less. The MRI score correctly reclassified the mass origin as nonadnexal with a sensitivity of 0.99 (95% CI, 0.98-0.99; 1360 of 1372 patients) and a specificity of 0.78 (95% CI, 0.71-0.85; 102 of 130 patients). Conclusions and Relevance: In this study, the O-RADS MRI score was accurate when stratifying the risk of malignancy in adnexal masses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.